Promising Results Reported for Prostate Cancer Focal Brachytherapy
In a small series, overall and disease-free survival rates were favorable.
In a small series, overall and disease-free survival rates were favorable.
Two-year and three-year biochemical progression-free survival rate of 100 percent for low-risk disease.
In a study with a follow-up period of 18 years, men treated with any other modality but radical prostatectomy had higher prostate cancer death risks.
A study presented at the 2018 ONS Annual Congress explored whether aromatherapy and reflexology can ease anxiety and pain for patients undergoing brachytherapy for cervical cancer.
ASCO and Cancer Care Ontario issued a joint update to guidelines for brachytherapy for prostate cancer that take into account new evidence.
An investigation on the late side effects of a combination of two forms of brachytherapy to treat cervical cancer has revealed that the technique delivers higher radiation doses to the tumor without additional treatment-related complications afterwards.
Brachytherapy, with or without external beam radiation, can improve survival in women with inoperable, early stage endometrial cancer.
High-dose-rate (HDR) brachytherapy is typically used as a dose-escalating boost for external beam radiotherapy for prostate cancer; however, some researchers believe it might be close to graduating to a viable monotherapy.
Specific guidance for delivering high dose-rate brachytherapy to improve quality and safety is offered in a new white paper from the American Society for Radiation Oncology (ASTRO).
Long-term outcomes of breast cancer patients receiving adjuvant accelerated partial breast irradiation after breast-conserving surgery show excellent tumor control with minimal late toxicity.